Long-Term Results of Topical Mitomycin C 0.02% for Primary and Recurrent Conjunctival-Corneal Intraepithelial Neoplasia

Long-Term Results of Topical Mitomycin C 0.02% for Primary and Recurrent Conjunctival-Corneal Intraepithelial Neoplasia

Author Ballalai, Priscilla Luppi Autor UNIFESP Google Scholar
Erwenne, Clelia M. Autor UNIFESP Google Scholar
Martins, Maria Cristina Autor UNIFESP Google Scholar
Lowen, Marcia S. Autor UNIFESP Google Scholar
Barros, Jeison N. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Purpose: To evaluate the efficacy, recurrence rate, and long-term complications of topical mitomycin C (MMC) 0.02% for conjunctival-corneal intraepithelial neoplasia (CCIN).Methods: A prospective, nonrandomized, noncontrolled study was conducted of patients with primary or recurrent CCIN treated with topical MMC 0.02%, four times per day, for 28 consecutive days. the main outcome measures were complete resolution of the neoplasia by slit-lamp examination and cytology I month after treatment, tumor recurrence, and long-term complications.Results: Between June 1999 and September 2005, 23 patients were included. Eighteen had primary CCIN (group 1) and 5 had recurrent CON (group 2). the mean follow-up was 46 months in group I and 54 months in group 2. All patients were treated with MMC 0.02% for 28 consecutive days. Complete resolution of the lesion was achieved in all patients after I month of treatment. Recurrence occurred in I patient (4.3%) after 24 months of treatment. Four patients developed corneal erosion (17.4%), 2 of them with primary CCIN and 2 with recurrent CCIN. Corneal erosion occurred 4 to 24 months after treatment and was treated successfully. the probability for corneal erosions by the log-rank test was equal for both groups (p = 0.1705).Conclusions: the use of topical MMC 0.02% for 28 consecutive days to treat primary or recurrent CCIN was effective and showed a low recurrence rate. Corneal erosion occurred in 17.4% of cases and can occur as late as 24 months after treatment.
Language English
Sponsor Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Date 2009-07-01
Published in Ophthalmic Plastic and Reconstructive Surgery. Philadelphia: Lippincott Williams & Wilkins, v. 25, n. 4, p. 296-299, 2009.
ISSN 0740-9303 (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 296-299
Origin http://dx.doi.org/10.1097/IOP.0b013e3181ac4c39
Access rights Closed access
Type Article
Web of Science ID WOS:000268288600010
URI http://repositorio.unifesp.br/handle/11600/31658

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account